

Hearing Examines Ways to Bolster Drug Safety

Congress considering boosting FDA's authority; agency would have more clout over product labeling.

BY JOYCE FRIEDEN
Associate Editor, Practice Trends

WASHINGTON — Congress is considering giving the Food and Drug Administration more authority over the pharmaceutical companies it deals with, but some legislators are warning against doing too much too fast.

"Changes to drug safety ... must be carefully considered to make sure they don't unduly impact patient access," Sen. Mike Enzi (R-Wyo.), chair of the Senate Health, Education, Labor, and Pensions Committee, said at a hearing on FDA oversight. "Congress needs to engage in strong oversight to maintain public confidence in the FDA."

Sandra Kweder, M.D., deputy director of the Office of New Drugs at the FDA's Center for Drug Evaluation and Research, told the Senate committee that in order to en-

sure drug safety, it would be helpful if the FDA had more clout. She noted that it took a lot of back-and-forth haggling just to get some earlier warnings added to the label.

"The most important lapse [with the safety concerns surrounding Vioxx] was the delay it took to get the information into the labeling; it took over a year," she said. "I think stronger ability to require changes in labeling would be very helpful."

The committee's ranking member, Sen. Edward Kennedy (D-Mass.), also spoke in favor of giving the agency greater labeling authority. "The FDA needs clear authority to require relabeling of a drug after approval once a risk is found," he said. "Negotiations with the drug company should never delay [that]."

Some observers said that although giving the agency more authority over label changes is a good idea, it only goes so far. "We all know product labeling does not

change provider behavior very much," said Arthur Levin, director of the Center for Medical Consumers in New York and the consumer representative on the FDA's Drug Safety and Risk Management advisory committee. Even if FDA does get more labeling authority, "we shouldn't count on it protecting the public from harm," Mr. Levin said at a teleconference announcing the release of a new survey on consumer attitudes about the FDA.

The survey of 1,000 adults nationwide was performed by pollster Celinda Lake and sponsored by a coalition of consumer groups. The results showed that only 14% of respondents had a great deal of confidence in the agency's ability to ensure the safety of prescription drugs. And 48% of respondents said they believed the FDA was too influenced by the industries over which it has jurisdiction.

Another subject discussed at the Senate hearing was the secrecy of clinical trial data. "I'd like to emphasize the importance of open access to data from clinical trials, including negative trials and unpublished research," David Fassler, M.D., a child and adolescent psychiatrist in Burlington, Vt., who testified on behalf of the American Academy of Child and Adolescent Psychiatry and the American Psychiatric Association.

In 2004, when Dr. Fassler testified on the question of whether there was a link between selective serotonin reuptake inhibitors (SSRIs) and suicide, "there were only four studies in the published literature on [the use of] SSRIs in adolescents. But I later learned that there were 11 unpublished studies whose results had been submitted to FDA. Parents clearly need access to this kind of evidence." ■

'The FDA needs clear authority to require relabeling of a drug after approval once a risk is found. Negotiations ... should never delay [that].'

CLASSIFIEDS

Also Available at www.eskinandallergynews.com

LABORATORIES

SLIDE PREPARATIONS

North Bay Histology Lab, Inc. offers slide preparations for only \$5.00 per H/E*. 2nd Opinion interpretation at \$23.00 per case. All supplies are free. Our turnaround time is 24 hours. All supplies and shipment of specimens/slides are free.

*Please call (415) 883-2510 for details; some restrictions apply.

Have questions on classifieds?
Call Andrea LaMonica
(800) 831-0569
for more information.

LOW-COST SLIDE PREPARATION

Borsting Laboratories, Inc. is a Histopathology Laboratory that has been processing dermatological specimens for more than 40 years. We are currently serving several hundred dermatologists throughout the United States. All supplies are free and we offer next day delivery via DHL Express at no charge to your clinic. Our turnaround time is less than 24 hours.

Borsting Laboratories also offers low-cost dermatopathological interpretation by Leon M. Edelstein, M.D., FASCP. All the microscopic interpretations will be called and faxed to your office.

We provide the highest quality slides while maintaining the lowest cost per H/E slide and special stain than any other laboratory.

PS. For a price list and our free Mailing Kit, call our Toll - Free line at (866) 883-5077.


KENDALL MEDICAL LAB

- H & E Slide Preparation
- Gross Report & Slide Preparation
- Microscopic Interpretation
- Detailed Slide Labels & Reports
- Custom Requisitions
- Free Supplies, Postage & Fax Results
- Overnight Delivery Available
- Special Stains Available
- Physician, Patient or Insurance Billing

1-800-444-2443

www.kendallmedicallab.com

CONTINUING EDUCATION



University of Pittsburgh Department of Dermatology

Training Program in Cosmetic & Dermatologic Surgery

The University of Pittsburgh Department of Dermatology is offering a one-year training program in Dermatologic Surgery, Cosmetic Dermatologic Surgery. Under the direction of Dr. Suzan Obagi, the program is designed to provide trainees with the experience necessary for the practice of modern cosmetic dermatologic surgery. Trainees will receive considerable experience in cosmetic surgery with significant exposure to general dermatologic surgery, cutaneous surgical oncology, and Mohs surgery.

This unique academically affiliated center offers the latest in cosmetic and laser surgery advances including tumescent liposuction of the body and face, blepharoplasties, rhytidectomies, fat augmentation, laser resurfacing, chemical resurfacing, microdermabrasion, soft-tissue fillers, Botox, sclerotherapy, and scar revision. The program will provide an opportunity for the trainee to become proficient performing laser surgeries utilizing the latest lasers including: 595 nm PDL, Nd:YAG laser, QS-Nd-YAG laser, Alexandrite laser, Cool Touch III laser, as well as an erbium:YAG with CO2 capabilities for skin resurfacing, and the Thermacool system.

A research project will be required to fulfill the requirements of the fellowship.

The training faculty includes:

Suzan Obagi, MD Assistant Professor of Dermatology, Program Director / Director, Cosmetic Surgery and Skin Health Center

Dominic Brandy, MD Director, Enhanced Images Cosmetic Surgery Center

James Bridenstine, MD Associate Professor of Dermatology, Director, Mohs Surgery

University of Pittsburgh School of Medicine and the UPMC Health System are equal opportunity employers. Applications from women and people from diverse racial ethnic and cultural backgrounds are encouraged.

BC/BE Dermatology applicants should submit a personal statement, CV, and 3 letters of recommendation (one from department chair) to Dr. Suzan Obagi, Dermatologic Surgery Training Program, c/o Dr. Suzan Obagi, Director, University of Pittsburgh, Department of Dermatology, Blaymore II, 1603 Carmody Court, Suite 103, Sewickley, PA. 15143 Phone: 724-940-SKIN (7546)

FOR SALE

For Sale Cosmetic Dermatology Equipment

Syneron Polaris "Elos technology" RF/laser unit for treatment of wrinkling & skin discoloration. 1 year old

Equipment used lightly in a private practice setting. Price considerably less than new or through brokers.

Please email equipment@agedefy.com